Himalaya Nutravedics India Shares List at 11.32% Premium at ₹118 on BSE SME

Himalaya Nutravedics India shares made their stock market debut on September 29, 2026, listing at ₹118 per share on the BSE SME platform, compared with the IPO issue price of ₹106 per share. The listing price represented an 11.32% premium over the issue price. 

Following the listing, the stock traded at ₹122.50, up 15.57% from the issue price and 3.81% from the listing price. During the session, Himalaya Nutravedics India shares touched a high of ₹123.90 and a low of ₹118, with around 7 lakh shares changing hands on the BSE at the 11:16 AM snapshot.

The listing followed the company's IPO, which was open for subscription from September 22 to September 24, 2026. The ₹26.50 crore book-built SME issue was subscribed 2.24 times overall. The IPO price band was fixed at ₹100 to ₹106 per share. 

Himalaya Nutravedics India manufactures, markets and distributes Ayurvedic and nutraceutical formulations. It also undertakes third-party contract manufacturing and produces formulations including softgel and hardgel capsules, tablets, liquid orals and medicated oils. 

Himalaya Nutravedics India IPO Listing Details

Himalaya Nutravedics India IPO was a ₹26.50 crore book-built SME issue comprising 24,99,600 equity shares and was entirely a fresh issue. The issue included a market-maker reservation of 1,26,000 shares. 

The IPO opened on September 22 and closed on September 24, 2026. Its price band was ₹100 to ₹106 per share and the final issue price was ₹106. The IPO was subscribed 2.24 times overall, with QIB subscription at 1 time, NII at 2.90 times and Individual Investors at 2.56 times. 

The company also raised ₹7.53 crore from anchor investors through the allotment of 7,10,400 shares at ₹106 per share on September 21. 

Himalaya Nutravedics India listed at ₹118 on BSE SME and subsequently traded at ₹122.50 at the reported morning snapshot.

- Issue Price: ₹106 per share
- BSE SME Listing Price: ₹118 per share
- Listing Premium: 11.32%
- Trading Price: ₹122.50 per share
- Change From Issue Price: +15.57%
- Intraday High: ₹123.90
- Intraday Low: ₹118
- Overall Subscription: 2.24 times
- Fresh Issue: ₹26.50 crore
- Offer for Sale: Nil
- Price Band: ₹100 to ₹106 per share
- IPO Open Date: September 22, 2026
- IPO Close Date: September 24, 2026
- Listing Date: September 29, 2026
- Exchange: BSE SME

First-Day Trading Performance

Listing Price: Himalaya Nutravedics India listed at ₹118 per share, ₹12 above its ₹106 issue price. This represented an 11.32% listing premium. 

Post-listing price: At the 11:16 AM snapshot, the shares traded at ₹122.50, representing a 15.57% premium over the IPO issue price and a 3.81% increase from the listing price. 

Intraday high: The stock touched ₹123.90, approximately 16.89% above the ₹106 issue price.

Intraday low: The shares touched a low of ₹118, the same as the listing price and 11.32% above the issue price. 

Volume: Around 7 lakh shares had changed hands on the BSE at the reported market snapshot. 

Subscription context: The IPO was subscribed 2.24 times overall. NII subscription stood at 2.90 times, Individual Investors at 2.56 times and QIB subscription at 1 time. 

Growth Drivers and Challenges

Growth Drivers

Product Portfolio: Himalaya Nutravedics India manufactures Ayurvedic and nutraceutical products across dosage forms including softgel and hardgel capsules, tablets, liquid orals and medicated oils.

Contract Manufacturing: Alongside its own manufacturing, marketing and distribution activities, the company undertakes third-party contract manufacturing for other Ayurvedic and nutraceutical businesses. 

Business Expansion: The company plans to allocate IPO proceeds towards branding, digital marketing and sales expansion, providing capital for broader business development.

Financial Growth: Total income increased to ₹43.12 crore in FY26 from ₹21 crore in FY25, while profit after tax increased to ₹7.39 crore from ₹2.23 crore. EBITDA increased to ₹8.10 crore from ₹2.99 crore.

Challenges

Working Capital Requirements: The company has identified working capital as a significant funding requirement and plans to allocate ₹13.75 crore of net IPO proceeds towards this purpose. 

Regulatory Exposure: Ayurvedic and nutraceutical products operate within regulatory frameworks governing manufacturing, product standards, labelling and marketing.

Brand-Building Execution: The company plans significant expenditure on business development and digital marketing, making effective deployment of these funds relevant to its expansion strategy.

Competitive Market: The Ayurvedic, wellness and nutraceutical markets include established brands as well as emerging manufacturers and contract manufacturing companies.

SME Scale: As an SME-listed company with a relatively smaller operating base, business performance can be more sensitive to changes in customer demand and working-capital requirements.

Utilisation of IPO Proceeds

Himalaya Nutravedics India's ₹26.50 crore IPO was entirely a fresh issue. There was no offer-for-sale component, meaning the proceeds from the fresh issue are intended for the company's stated corporate requirements. 

The company plans to use ₹13.75 crore from the net proceeds for working capital requirements and another ₹7.50 crore for business development and digital marketing activities. The remaining proceeds are intended for general corporate purposes. 

Principal uses include:
- ₹13.75 crore towards funding working capital requirements.
- ₹7.50 crore towards business development and digital marketing activities.
- Remaining proceeds towards general corporate purposes. 

Following the IPO, promoter and promoter group shareholding stood at 68.13%, compared with 95.14% before the issue. 

Business and IPO Overview

Himalaya Nutravedics India is engaged in manufacturing, marketing and distributing Ayurvedic and nutraceutical formulations in India. The company also provides third-party contract manufacturing services to other Ayurvedic and nutraceutical companies. 

Its portfolio includes formulations across several dosage forms, including softgel capsules, hardgel capsules, tablets, liquid orals and medicated oils covering multiple wellness and therapeutic segments. Business Standard
As of July 31, 2026, the company had 86 employees. For FY26, total income stood at ₹43.12 crore, compared with ₹21 crore in FY25. Profit after tax increased to ₹7.39 crore from ₹2.23 crore, while EBITDA rose to ₹8.10 crore from ₹2.99 crore. 

The ₹26.50 crore IPO comprised an entirely fresh issue of 24,99,600 shares. The price band was ₹100 to ₹106 per share, and the IPO was open for subscription from September 22 to September 24. The issue received 2.24 times overall subscription.

Himalaya Nutravedics India listed on BSE SME at ₹118 on September 29, an 11.32% premium to the ₹106 issue price. At the 11:16 AM market snapshot, the stock traded at ₹122.50 after reaching an intraday high of ₹123.90 and a low of ₹118, with around 7 lakh shares changing hands.